Literature DB >> 9880200

Serum levels of VEGF and basic FGF in the subacute phase of myocardial infarction.

A Kawamoto1, H Kawata, Y Akai, Y Katsuyama, E Takase, Y Sasaki, S Tsujimura, Y Sakaguchi, M Iwano, S Fujimoto, T Hashimoto, K Dohi.   

Abstract

We examined serial changes in serum levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) measured by ELISAs in 45 patients with acute myocardial infarction (AMI) who received heparin intravenously for 3 to 5 days after the onset and in 30 control subjects with an old myocardial infarction. To evaluate the effect of heparin on these serum levels, heparin was administered intravenously in 10 patients with AMI on day 21. Blood samples were obtained from all AMI patients on days 1, 2, 3, 7, 14, 21, and 28 and from 10 AMI patients before and 1 h after heparin administration. Serum VEGF level was significantly reduced after heparin administration (P<0.001). Serum samples from day 1 to 3 were therefore excluded from the subsequent analysis. Serum VEGF level in AMI patients was significantly higher on day 7 than in the control subjects (P<0.0001), and then decreased over time (P<0.0001). The serum VEGF level on day 7 was independently associated with the peak serum CK level (P<0.05). The serum bFGF level did not differ significantly between the AMI patients and the control subjects. In conclusion, the serum VEGF level may be selectively elevated during the healing process after AMI.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9880200     DOI: 10.1016/s0167-5273(98)00251-4

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Y Wang; H E Johnsen; S Mortensen; L Bindslev; R Sejersten Ripa; M Haack-Sørensen; E Jørgensen; W Fang; J Kastrup
Journal:  Heart       Date:  2005-10-26       Impact factor: 5.994

Review 2.  Fibroblast growth factor-2 and cardioprotection.

Authors:  Elissavet Kardami; Karen Detillieux; Xin Ma; Zhisheng Jiang; Jon-Jon Santiago; Sarah K Jimenez; Peter A Cattini
Journal:  Heart Fail Rev       Date:  2007-12       Impact factor: 4.214

3.  MicroRNA-135a-3p regulates angiogenesis and tissue repair by targeting p38 signaling in endothelial cells.

Authors:  Basak Icli; Winona Wu; Denizhan Ozdemir; Hao Li; Stefan Haemmig; Xin Liu; Giorgio Giatsidis; Henry S Cheng; Seyma Nazli Avci; Merve Kurt; Nathan Lee; Raphael Boesche Guimaraes; Andre Manica; Julio F Marchini; Stein Erik Rynning; Ivar Risnes; Ivana Hollan; Kevin Croce; Dennis P Orgill; Mark W Feinberg
Journal:  FASEB J       Date:  2019-01-22       Impact factor: 5.191

4.  Stable phase post-MI patients have elevated VEGF levels correlated with inflammation markers, but not with atherosclerotic burden.

Authors:  Barbara ErŽen; Mira Šilar; Mišo Šabovič
Journal:  BMC Cardiovasc Disord       Date:  2014-11-22       Impact factor: 2.298

5.  Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction.

Authors:  Ignacio Cruz-Gonzalez; Pedro Pabón; Alicia Rodríguez-Barbero; Javier Martín-Moreiras; Miguel Pericacho; Pedro L Sánchez; Victor Ramirez; María Sánchez-Ledesma; Francisco Martín-Herrero; Javier Jiménez-Candil; Andrew O Maree; Angel Sánchez-Rodríguez; Cándido Martín-Luengo; José M López-Novoa
Journal:  J Cell Mol Med       Date:  2008-06       Impact factor: 5.310

6.  Serum vascular endothelial growth factor level is elevated in patients with impaired glucose tolerance and type 2 diabetes mellitus.

Authors:  Xiaomeng Sun; Heng Zhang; Jia Liu; Guang Wang
Journal:  J Int Med Res       Date:  2019-09-23       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.